Our Articles
Explore our thought leadership article library, where you can find a wealth of insights on regulatory intelligence, industry updates, and the latest pharmaceutical and biotechnology developments.
Making the Most of Opportunities to Interact with The US FDA.
FDA offers formal advice at no cost to developers of medicines regulated by both CDER and CBER, with the aim of supporting medicinal product development from Phase 1 through to marketing.
Post-Brexit Transition Period Changes. UK’s New Regulatory Landscape.
Following the end of the United Kingdom’s Brexit transition period on 31 December 2020, the MHRA will implement a number of changes as the UK forges its new regulatory system.